



Company Overview

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

[Sign up here](#) to receive notices about press releases and SEC filings.

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 28 2024, 7:00 AM EDT

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 21 2024, 4:30 PM EDT

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Mar 15 2024, 8:00 AM EDT

Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	27.43m
Last Price	\$1.67
52-Week	\$0.622 - \$2.50

04/09/2024 04:00 PM EDT

Investor Relations

ir@iterumtx.com

Management Team

Corey N. Fishman

Chief Executive Officer

Dr. Sailaja Puttagunta

Chief Medical Officer

Judith M. Matthews

Chief Financial Officer

Tom Loughman, PhD

Senior Vice President, Technical Operations

Louise Barrett

Senior Vice President, Legal Affairs

Steven I. Aronin, MD

Senior Vice President and Head of Clinical Development

Iterum Therapeutics plc

200 S Wacker Drive
Suite 3100
Chicago, IL 60606
USA

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.